Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine

The Decoder
AI Business

US pharmaceutical giant Eli Lilly is betting big on AI-driven drug development, signing a $2.75B deal with Hong Kong-listed Insilico Medicine. The article Eli Lilly signs $2.